Modulation of NK, T, & B cell sub-populations by Pomalidomide predicts favorable progression-free survival (PFS): Results from a large randomized clinical trial in relapsed/refractory myeloma

Authors :: Prabhal Rao
Teresa Peluso
Suzan Lazo-Kallanian
Hervé Avet-Loiseau
Paul G. Richardson
Alexander T Heubeck
Meral Beksac
Meletios A. Dimopoulos
Kenneth C. Anderson
Anjan Thakurta
William E. Pierceall
Mehmet Kemal Samur
Mariateresa Fulciniti
Kevin Hong
mohamad hussain
Sanika Derebail
John F. Daley
Srikanth Talluri
Lakshmi B. Potluri
Michael J Buonopane
Eric Haas
Tsvetan Biyukov
Nikhil C. Munshi
Source :: Clinical Lymphoma Myeloma and Leukemia. 19:e167
Publication Year :: 2019
Publisher :: Elsevier BV, 2019.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Sub populations
business.industry
Hematology
Pomalidomide
law.invention
medicine.anatomical_structure
Randomized controlled trial
law
Internal medicine
Relapsed refractory
medicine
Progression-free survival
business
B cell
medicine.drug

Full Text Access

Tools